Jazz Pharmaceuticals (JAZZ) EVP has 6,209 shares withheld for taxes

Rhea-AI Filing Summary

Jazz Pharmaceuticals EVP Robert Iannone, Global Head of R&D and CMO, reported a tax-related share disposition. On March 5, 2026, 6,209 ordinary shares were withheld at a price of 188.69 per share to satisfy tax obligations from the vesting of previously granted restricted stock units.

Following this tax-withholding disposition, Iannone directly holds 88,871 ordinary shares of Jazz Pharmaceuticals. This transaction reflects administrative share withholding rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Iannone Robert

Role EVP, Global Head of R&D & CMO

Type	Security	Shares	Price	Value
Tax Withholding	Ordinary Shares	6,209	$188.69	$1.17M

Holdings After Transaction: Ordinary Shares — 88,871 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Iannone Robert

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Global Head of R&D & CMO

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/05/2026		F(1)		6,209	D	$188.69	88,871	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

	By: /s/Paz Dizon, as attorney in fact For: Robert Iannone	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Jazz (JAZZ) executive Robert Iannone report?

Robert Iannone reported a tax-withholding disposition of 6,209 Jazz ordinary shares. The shares were withheld on March 5, 2026, to cover tax obligations triggered by the vesting of previously granted restricted stock units, rather than sold in the open market.

How many Jazz (JAZZ) shares were withheld for Robert Iannone’s taxes?

A total of 6,209 ordinary shares of Jazz Pharmaceuticals were withheld for Robert Iannone’s tax obligations. This withholding occurred when a portion of his restricted stock units vested, using shares instead of cash to satisfy the related tax liability.

At what price per share were Robert Iannone’s Jazz (JAZZ) shares withheld?

The 6,209 Jazz ordinary shares tied to Robert Iannone’s tax withholding were valued at 188.69 per share. This price was used to determine how many shares were needed to satisfy the tax obligations arising from the vesting restricted stock units.

How many Jazz (JAZZ) shares does Robert Iannone hold after this Form 4 transaction?

After the reported tax-withholding transaction, Robert Iannone directly owns 88,871 ordinary shares of Jazz Pharmaceuticals. This figure reflects his holdings following the 6,209 shares withheld to cover taxes from the vesting of restricted stock units.

Was Robert Iannone’s Jazz (JAZZ) Form 4 a sale in the open market?

No, the Form 4 reports a tax-withholding disposition, not an open-market sale. The 6,209 shares were withheld by Jazz Pharmaceuticals to settle tax obligations from vesting restricted stock units, rather than sold through normal trading on an exchange.

What triggered the tax-withholding disposition reported by Jazz (JAZZ) executive Robert Iannone?

The disposition was triggered by the vesting of previously granted restricted stock units. When part of these units vested, 6,209 Jazz ordinary shares were withheld to cover the resulting tax obligations instead of paying those taxes in cash.